Haloperidol is one of 20 ‘essential’ medications in palliative care. Its use is widespread in palliative care patients. The pharmacology of haloperidol is complex and the extent and severity of some of its adverse effects, particularly extrapyramidal adverse effects (EPS), may be related to the route of administration. Indications for the use of haloperidol in palliative care are nausea and vomiting and delirium. Adverse effects include EPS and QT prolongation. Sedation is not a common adverse effect of haloperidol. It is important that palliative care practitioners have a comprehensive understanding of the indications, doses, adverse effects and pharmacology of haloperidol. This review is intended to address these issues.
Settle EC, Ayd FJ. Haloperidol: a quarter century of experience. J Clin Psychiatry1983; 44: 440-448.
2.
Dickerson D. The 20 essential drugs in palliative care. Eur J Palliat Care1999; 6: 130-135.
3.
Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther2002; 72: 438-452.
4.
Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M eds. Metabolic drug interactions. Philadelphia, PA: Lippincott Williams and Wilkins, 2000: 247-249.
5.
Forsman AO. Individual variability in response to haloperidol. Proc R Soc Med1976; 69: 9-13.
6.
Breitbart W, Sparrow B. Management of delirium in the terminally ill. Prog Palliat Care1998; 6: 107-113.
7.
Chang WH, Lam YWF, Jann MW, Chen H. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology1992; 106: 517-522.
8.
Nielssen O, Buhrich N, Finlay-Jones R. Intravenous sedation of involuntary psychiatric patients in New South Wales. Aust NZ J Psychiatry1997; 31: 273-278.
9.
Urlich S, Neuhof S, Braun V, Meyer FP. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Int Clin Psychopharmacol1999; 14: 219-228.
10.
Dollery C, Boobis A, Rawlins M, Thomas S, Wilkins M eds. Therapeutic drugs. 2nd ed.Edinburgh: Churchill Livingstone, 1999: H3-H9.
11.
Maldonado JR. Intravenous versus oral haloperidol: an evaluation of the incidence of extra-pyramidal symptoms. Psychosomatics2000; 41: 169-170.
12.
Skinner J, Skinner A. Levomepromazine for nausea and vomiting in advanced cancer. Hosp Med1999; 60: 568-570.
13.
Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systemic review. J Pain Symptom Manage2001; 22: 631-634.
14.
Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Symptom Manage1994; 9: 48-50.
15.
McQuillan R, Finlay I, Branch C, Roberts D, Spencer M. Improving analgesic prescribing in a general teaching hospital. J Pain Symptom Manage1996; 11: 172-180.
16.
Schwartz TL, Masand MD. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics2002; 43: 171-174.
17.
Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics2002; 43: 175-182.
18.
Morita T, Tsunoda J, Inoue S, Chihara S. Communication capacity scale and agitation distress scale to measure the severity of delirium in terminally ill cancer patients: a validation study. Palliat Med2001; 15: 197-206.
19.
Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage1999; 17: 219-223.
20.
Jann MW, Chang W-H, Davis CM, Chen T-Y, Deng H-C, Lung F-W, Ereshefsky L, Saklad SR, Richards AL. Haloperidol and reduced haloperidol plasma levels in Chinese vs non-Chinese psychiatric patients. Psychiatry Res1989; 30: 45-52.
21.
Brietbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, Cobera K, Raymond S, Lund S, Jocobsen P. A double-blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry153: 231-237.
22.
Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmac-other1995; 29: 690-693.
23.
Menza M, Murray GB, Holmes VF, Rafuls WA. Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung1988; 17: 238-241.
24.
Murray GE. Confusion, delirium and dementia. In Hackett TP, Cassem NH eds. Massachusetts General Hospital handbook of general hospital psychiatry. 2nd ed.Littleton: PSG Publishing Company Inc, 1987: 110-111.
25.
Van Putten T, Marder SR, Mintz J, Poland E. Haloper-idol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry1992; 149: 500-505.
26.
Cassarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med2001; 135: 32-40.
27.
Lane H-Y, Chang W-H, Chang Y-C, Hu OY-P, Lin H-N, Jann MW, Hu W-H. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. Psychiatry Res1997; 72: 127-132.
28.
Conacher GN, Marazki MO, Evans DAP, Bertilsson L, Sjoqvist F. Acute dystonic reactions in Saudi Arabian psychiatric patients treated with haloperidol. Acta Psychiatr Scand1987; 75: 333-334.
29.
Fainsinger R, Bruera E. Treatment of delirium in a terminally ill patient. J Pain Symptom Manage1992; 7: 54-56.
30.
Ayd FJ. Haloperidol: a new profile?Proc R Soc Med1976: 69suppl 1, 16-16.
Bazire S. Psychotropic drug directory. Dinton: Mark Allen Publishing Ltd, 2000: 85-85.
33.
Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet2000; 355: 1048-1052.
34.
Macleod AD. Use of sedatives in palliative medicine (letter). Pall Med1997; 11: 493-496.
